SI-BONE（2K3）株式概要医療機器メーカーであるSI-BONE, Inc.は、米国内外の仙骨骨盤の筋骨格系障害の解決に注力している。 詳細2K3 ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長1/6過去の実績0/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より70.4%で取引されている 収益は年間13.98%増加すると予測されています 過去5年間の収益は年間18.8%増加しました。 リスク分析現在は利益が出ておらず、今後3年間で利益が出る見込みはない 過去3か月間に大規模なインサイダー売却が発生 すべてのリスクチェックを見る2K3 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW492,375 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG492,375 investors already sharing narrativesYour Fair Value€Current Price€14.4013.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-62m397m2016201920222025202620282031Revenue US$396.6mEarnings US$51.3mAdvancedSet Fair ValueView all narrativesSI-BONE, Inc. 競合他社Eckert & ZieglerSymbol: XTRA:EUZMarket cap: €994.3mDrägerwerk KGaASymbol: XTRA:DRW3Market cap: €1.5bStratecSymbol: XTRA:SBSMarket cap: €218.8mCarl Zeiss MeditecSymbol: XTRA:AFXMarket cap: €2.4b価格と性能株価の高値、安値、推移の概要SI-BONE過去の株価現在の株価US$14.4052週高値US$17.9052週安値US$9.65ベータ0.701ヶ月の変化22.03%3ヶ月変化33.33%1年変化n/a3年間の変化-40.50%5年間の変化-40.50%IPOからの変化-13.98%最新ニュースBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. CEO & Director Laura Francis was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • May 12SI-BONE, Inc. Raises Earnings Guidance for the Year 2026SI-BONE, Inc. raised earnings guidance for the year 2026. For the year, the company worldwide revenue expectation to be in the range of $230 million to $233 million, implying year-over-year growth of 14% to 16% compared to previous guidance of $228.5 million - $232.5 million.お知らせ • Apr 22SI-BONE, Inc., Annual General Meeting, Jun 04, 2026SI-BONE, Inc., Annual General Meeting, Jun 04, 2026.お知らせ • Apr 21SI-BONE, Inc. to Report Q1, 2026 Results on May 11, 2026SI-BONE, Inc. announced that they will report Q1, 2026 results After-Market on May 11, 2026お知らせ • Feb 24+ 1 more updateSI-BONE, Inc. Provides Earnings Guidance for the Year 2026SI-BONE, Inc. provided earnings guidance for the year 2026. For the year, the company expects worldwide revenue to be in the range of $228.5 millionto $232.5 million, implying year-over-year growth of ~14% to ~16%.お知らせ • Feb 03SI-BONE, Inc. to Report Q4, 2025 Results on Feb 23, 2026SI-BONE, Inc. announced that they will report Q4, 2025 results After-Market on Feb 23, 2026最新情報をもっと見るRecent updatesBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. CEO & Director Laura Francis was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • May 12SI-BONE, Inc. Raises Earnings Guidance for the Year 2026SI-BONE, Inc. raised earnings guidance for the year 2026. For the year, the company worldwide revenue expectation to be in the range of $230 million to $233 million, implying year-over-year growth of 14% to 16% compared to previous guidance of $228.5 million - $232.5 million.お知らせ • Apr 22SI-BONE, Inc., Annual General Meeting, Jun 04, 2026SI-BONE, Inc., Annual General Meeting, Jun 04, 2026.お知らせ • Apr 21SI-BONE, Inc. to Report Q1, 2026 Results on May 11, 2026SI-BONE, Inc. announced that they will report Q1, 2026 results After-Market on May 11, 2026お知らせ • Feb 24+ 1 more updateSI-BONE, Inc. Provides Earnings Guidance for the Year 2026SI-BONE, Inc. provided earnings guidance for the year 2026. For the year, the company expects worldwide revenue to be in the range of $228.5 millionto $232.5 million, implying year-over-year growth of ~14% to ~16%.お知らせ • Feb 03SI-BONE, Inc. to Report Q4, 2025 Results on Feb 23, 2026SI-BONE, Inc. announced that they will report Q4, 2025 results After-Market on Feb 23, 2026お知らせ • Nov 11Si-Bone, Inc. Updates Earnings Guidance for the Year 2025Si-Bone, Inc. updated earnings guidance for the year 2025. For the year, the company now expects Revenue of $198 Million - $200 Million against previous guidance of $195 Million - $198 Million.お知らせ • Oct 21SI-BONE, Inc. to Report Q3, 2025 Results on Nov 10, 2025SI-BONE, Inc. announced that they will report Q3, 2025 results After-Market on Nov 10, 2025お知らせ • Aug 05+ 1 more updateSI-BONE, Inc. Revises Financial Guidance for the Full Year of 2025SI-BONE, Inc. revises financial guidance for the full year of 2025. For the period, the company expects worldwide revenue to be in the range of $195 million to $198 million, implying year-over-year growth of approximately 17% to approximately 18% against pervious guidance of $193.5 million to $197.5 million, implying year-over-year growth of approximately 16% to approximately 18%.お知らせ • Jul 15SI-BONE, Inc. to Report Q2, 2025 Results on Aug 04, 2025SI-BONE, Inc. announced that they will report Q2, 2025 results After-Market on Aug 04, 2025お知らせ • Jun 30+ 4 more updatesSI-BONE, Inc.(NasdaqGM:SIBN) dropped from Russell Microcap Value IndexSI-BONE, Inc.(NasdaqGM:SIBN) dropped from Russell Microcap Value Indexお知らせ • May 06SI-BONE, Inc. Revises Earnings Guidance for the Year 2025SI-BONE, Inc. revised earnings guidance for the year 2025. The company expects 2025 worldwide revenue to be in the range of $193.5 million to $197.5 million, compared to the prior guidance of $193.5 million to $195.5 million.お知らせ • Apr 28SI-BONE, Inc., Annual General Meeting, Jun 05, 2025SI-BONE, Inc., Annual General Meeting, Jun 05, 2025.お知らせ • Apr 15SI-BONE, Inc. to Report Q1, 2025 Results on May 05, 2025SI-BONE, Inc. announced that they will report Q1, 2025 results After-Market on May 05, 2025お知らせ • Feb 25SI-BONE, Inc. Provides Earnings Guidance for the Year 2025SI-BONE, Inc. provided earnings guidance for the year 2025. For the year 2025, the company expects worldwide revenue to be in the range of $193.5 million to $195.5 million, implying year-over-year growth of ~16% to ~17%.お知らせ • Feb 04SI-BONE, Inc. to Report Q4, 2024 Results on Feb 24, 2025SI-BONE, Inc. announced that they will report Q4, 2024 results After-Market on Feb 24, 2025Reported Earnings • Nov 14Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.25 loss in 3Q 2023)Third quarter 2024 results: US$0.16 loss per share (improved from US$0.25 loss in 3Q 2023). Revenue: US$40.3m (up 19% from 3Q 2023). Net loss: US$6.58m (loss narrowed 34% from 3Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.お知らせ • Nov 14SI-BONE, Inc. Updates Financial Guidance for the Year 2024SI-BONE, Inc. updated financial guidance for the year 2024. For the period, the company expects worldwide revenue guidance to be in the range of $165 million to $166 million compared to the prior guidance of $165 million to $167 million. The updated guidance implies annual revenue growth of approximately 19% to approximately 20%.お知らせ • Oct 23SI-BONE, Inc. to Report Q3, 2024 Results on Nov 12, 2024SI-BONE, Inc. announced that they will report Q3, 2024 results After-Market on Nov 12, 2024お知らせ • Oct 10SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture FixationSI-BONE, Inc. announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNT™? Implant System (TNT). Designed to address the anatomic and biomechanical challenges of pelvic fragility fractures, particularly in patients with poor bone quality, TNT offers a significant advancement over traditional cannulated screws. TNT, which received 510(k) clearance in August 2024 and was awarded Breakthrough Device Designation by the FDA, is the first 3D-printed transiliac-transsacral screw cleared for market use in the U.S. It features a pelvic fragility-specific design to improve initial fixation and reduce the risk of screw backout. Among the first surgeons to perform procedures with TNT were Edward Westrick, MD, at Allegheny General Hospital in Pittsburgh, PA, Reza Firoozabadi, MD, at Harborview Medical Center in Seattle, WA, J.D. Black, MD, at Kadlec Regional Medical Center in Richland, WA, and Brian Cunningham, MD, at Methodist Hospital - HealthPartners in St. Louis Park, MN.Recent Insider Transactions • Aug 22CEO & Director recently sold €126k worth of stockOn the 16th of August, Laura Francis sold around 10k shares on-market at roughly €12.59 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Laura has been a net seller over the last 12 months, reducing personal holdings by €876k.Reported Earnings • Aug 06Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.30 loss in 2Q 2023)Second quarter 2024 results: US$0.22 loss per share (improved from US$0.30 loss in 2Q 2023). Revenue: US$40.0m (up 20% from 2Q 2023). Net loss: US$8.94m (loss narrowed 20% from 2Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.お知らせ • Aug 06SI-BONE, Inc. Revises Financial Guidance for 2024SI-BONE, Inc. revised financial guidance for 2024. The company expects revenue to be in the range of $165 million to $167 million, an increase from the previous guidance of $164 million to $166 million. Compared to 2023, the updated guidance translates to growth of ~19% to ~20%, versus growth of ~18% to ~20% implied in the earlier guidance.New Risk • Jul 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$30m net loss in 2 years). Share price has been volatile over the past 3 months (6.7% average weekly change). Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Significant insider selling over the past 3 months (€199k sold).お知らせ • Jul 16SI-BONE, Inc. to Report Q2, 2024 Results on Aug 05, 2024SI-BONE, Inc. announced that they will report Q2, 2024 results After-Market on Aug 05, 2024New Risk • Jun 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$30m net loss in 2 years). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Significant insider selling over the past 3 months (€235k sold).お知らせ • May 08Si-Bone, Inc. Increases Revenue Guidance for 2024SI-BONE, Inc. increased revenue guidance for 2024. Company updated 2024 worldwide revenue guidance to be in the range of $164 million to $166 million, an increase from the previous guidance of $162 million to $165 million. Compared to 2023, the updated guidance translates to growth of ~18% to ~20%, versus growth of ~17% to ~19% implied in the earlier guidance.Reported Earnings • May 07First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.32 loss in 1Q 2023)First quarter 2024 results: US$0.27 loss per share (improved from US$0.32 loss in 1Q 2023). Revenue: US$37.9m (up 16% from 1Q 2023). Net loss: US$10.9m (loss narrowed 2.0% from 1Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. CEO & Director Laura Francis was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • May 01SI-BONE, Inc., Annual General Meeting, Jun 25, 2024SI-BONE, Inc., Annual General Meeting, Jun 25, 2024, at 08:00 Pacific Standard Time. Agenda: To elect the Board of Director’s two nominees for director to serve until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified; To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to discuss other matters.お知らせ • Apr 16SI-BONE, Inc. to Report Q1, 2024 Results on May 06, 2024SI-BONE, Inc. announced that they will report Q1, 2024 results After-Market on May 06, 2024New Risk • Mar 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$43m Forecast net loss in 3 years: US$20m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$20m net loss in 3 years). Shareholders have been diluted in the past year (19% increase in shares outstanding). Significant insider selling over the past 3 months (€1.2m sold).お知らせ • Feb 29SI-BONE, Inc. Provides Earnings Guidance for the Year 2024SI-BONE, Inc. provided earnings guidance for the year 2024. For the year, the company expects worldwide revenue to be between $162 million to $165 million, implying year-over-year growth of approx. 17% to approx. 19%.Reported Earnings • Feb 27Full year 2023 earnings released: US$1.13 loss per share (vs US$1.79 loss in FY 2022)Full year 2023 results: US$1.13 loss per share (improved from US$1.79 loss in FY 2022). Revenue: US$138.9m (up 31% from FY 2022). Net loss: US$43.3m (loss narrowed 29% from FY 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Breakeven Date Change • Feb 27Forecast to breakeven in 2026The 8 analysts covering SI-BONE expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 17% per year to 2025. The company is expected to make a profit of US$3.50m in 2026. Average annual earnings growth of 40% is required to achieve expected profit on schedule.Recent Insider Transactions • Feb 23CEO & Director recently sold €751k worth of stockOn the 16th of February, Laura Francis sold around 39k shares on-market at roughly €19.45 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Laura has been a net seller over the last 12 months, reducing personal holdings by €1.1m.お知らせ • Feb 06SI-BONE, Inc. to Report Q4, 2023 Results on Feb 26, 2024SI-BONE, Inc. announced that they will report Q4, 2023 results After-Market on Feb 26, 2024お知らせ • Jan 30SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and ApplicationSI-BONE, Inc. announces FDA 510(k) premarket clearance of the iFuse Bedrock Granite® Implant System (Granite) in a smaller (9.5 mm) diameter with both an expanded indication in pediatric patients and an expanded application that includes use in the S1 trajectory. When placed across the SI joint, the Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for multi-segment spinal fusion. This 510(k) clearance follows the initial clearance of the iFuse Bedrock Granite System in May 2022 that included implants of 10.5 mm and 11.5 mm in diameter. The iFuse Bedrock Granite System was also awarded a Breakthrough Device Designation (BDD) by the Food & Drug Administration (FDA) and a New Technology Add-on Payment (NTAP) by the Centers for Medicare and Medicaid Services (CMS).Breakeven Date Change • Jan 20Forecast to breakeven in 2026The 8 analysts covering SI-BONE expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$8.50m in 2026. Average annual earnings growth of 27% is required to achieve expected profit on schedule.お知らせ • Jan 09SI-Bone, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023SI-BONE, Inc. provided revenue guidance for the fourth quarter and full year 2023. For the fourth quarter, the company worldwide revenue expected to be in the range of $38.5-$38.7 million, representing growth of approximately 21% compared to the prior year period and U.S. revenue expected to be in the range of $36.5-$36.6 million, representing growth of approximately 22% compared to the prior year period.For the fiscal year, the company worldwide revenue expected to be in the range of $138.5-138.7 million, representing growth of approximately 30% compared to the prior year period and U.S. revenue expected to be in the range of $130.5-$130.6 million, representing growth of approximately 32% compared to the prior year period.Recent Insider Transactions • Nov 24Executive Chairman recently sold €130k worth of stockOn the 16th of November, Jeffrey Dunn sold around 8k shares on-market at roughly €16.29 per share. This transaction amounted to 7.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Jeffrey has been a net seller over the last 12 months, reducing personal holdings by €592k.お知らせ • Nov 09SI-BONE, Inc. Increases Earnings Guidance for the Full Year 2023SI-BONE, Inc. increased earnings guidance for the full year 2023. For the period, the company increased worldwide revenue to be in the range of $136 million to $137 million from the previous guidance of $132 million to $134 million. The updated guidance translates to growth of approximately 28% to 29% compared to fiscal year 2022, versus the previous revenue growth of approximately 24% to 26%.Reported Earnings • Nov 09Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.41 loss in 3Q 2022)Third quarter 2023 results: US$0.25 loss per share (improved from US$0.41 loss in 3Q 2022). Revenue: US$34.0m (up 29% from 3Q 2022). Net loss: US$10.0m (loss narrowed 29% from 3Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 3% per year.New Risk • Nov 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.1% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$12m net loss in 3 years). Shareholders have been diluted in the past year (17% increase in shares outstanding). Significant insider selling over the past 3 months (€1.1m sold).お知らせ • Oct 17SI-BONE, Inc. to Report Q3, 2023 Results on Nov 06, 2023SI-BONE, Inc. announced that they will report Q3, 2023 results After-Market on Nov 06, 2023お知らせ • Sep 06SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera 5.5/6.0 System RodsSI-BONE, Inc. confirmed that certain CD Horizon® Solera® 5.5mm and 6.0mm posterior spinal fixation rods manufactured by Medtronic Sofamor Danek USA Inc., a division of Medtronic plc, meet SI-BONE’s criteria for compatibility with iFuse Bedrock Granite® indicated in the Granite implant’s instructions for use. A complete list of Medtronic Solera® rods meeting the criteria for compatibility described in Granite’s cleared labeling is available on SI-BONE’s website. The iFuse Bedrock Granite implant was cleared by FDA on May 26, 2022. FDA recognized the Granite implant’s significant advantages over existing approved or cleared alternatives in designating the product as a Breakthrough Device. CMS subsequently adopted a New Technology Add-on Payment of up to $9,828 per procedure, based on the individual hospital’s costs, for procedures reimbursed under the Medicare program and incorporating this new technology.Recent Insider Transactions • Aug 21CEO & Director recently sold €173k worth of stockOn the 16th of August, Laura Francis sold around 9k shares on-market at roughly €19.21 per share. This transaction amounted to 4.6% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €561k. Laura has been a net seller over the last 12 months, reducing personal holdings by €591k.Recent Insider Transactions • Aug 13Independent Director recently sold €561k worth of stockOn the 9th of August, John Freund sold around 30k shares on-market at roughly €18.71 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.4m more than they bought in the last 12 months.お知らせ • Aug 10SI-BONE, Inc. Revises Revenue Guidance for the Year 2023SI-BONE, Inc. revised revenue guidance for the year 2023. The company is increasing its 2023 worldwide revenue guidance to be in the range of $132 million to $134 million from the previous guidance of $128 million to $131 million.Reported Earnings • Aug 08Second quarter 2023 earnings released: US$0.30 loss per share (vs US$0.54 loss in 2Q 2022)Second quarter 2023 results: US$0.30 loss per share (improved from US$0.54 loss in 2Q 2022). Revenue: US$33.3m (up 30% from 2Q 2022). Net loss: US$11.2m (loss narrowed 40% from 2Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.お知らせ • Jul 18SI-BONE, Inc. to Report Q2, 2023 Results on Aug 07, 2023SI-BONE, Inc. announced that they will report Q2, 2023 results After-Market on Aug 07, 2023Recent Insider Transactions • May 22CEO & Director recently sold €206k worth of stockOn the 16th of May, Laura Francis sold around 9k shares on-market at roughly €22.87 per share. This transaction amounted to 4.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Laura has been a net seller over the last 12 months, reducing personal holdings by €507k.お知らせ • May 06SI-BONE, Inc. has completed a Follow-on Equity Offering in the amount of $83.05 million.SI-BONE, Inc. has completed a Follow-on Equity Offering in the amount of $83.05 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,775,000 Price\Range: $22Reported Earnings • May 03First quarter 2023 earnings released: US$0.32 loss per share (vs US$0.52 loss in 1Q 2022)First quarter 2023 results: US$0.32 loss per share (improved from US$0.52 loss in 1Q 2022). Revenue: US$32.7m (up 46% from 1Q 2022). Net loss: US$11.1m (loss narrowed 36% from 1Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.お知らせ • Feb 07SI-BONE, Inc. to Report Q4, 2022 Results on Feb 27, 2023SI-BONE, Inc. announced that they will report Q4, 2022 results After-Market on Feb 27, 2023お知らせ • Jan 10SI-BONE, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022SI-BONE, Inc. provided preliminary unaudited revenue guidance for the fourth quarter and full year of 2022. For the quarter, the company expects worldwide revenue to be in the range of $31.7 million to $31.9 million, representing growth of approximately 26% compared to the prior year period. U.S. revenue to be in the range of $29.8 million to $29.9 million, representing growth of approximately 28% compared to the prior year period.For the full year, the company expects worldwide revenue to be in the range of $106.1 million to $106.3 million, representing growth of approximately 18% compared to the prior year period. U.S. revenue to be in the range of $98.6 million to $98.7 million, representing growth of approximately 19% compared to the prior year period.お知らせ • Dec 28SI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite(R) Implant SystemSI-BONE, Inc. announced an additional FDA clearance for iFuse Bedrock Granite. New cleared indications include use with a wide variety of commercially available pedicle screw system rods. Adult spinal deformity is a complex clinical problem to treat, with lumbopelvic fixation failure rates reported at 24%.1 Surgeons have adopted different strategies involving preoperative planning to improve spinal alignment, biologics, and next-generation pelvic fixation implants to help improve surgical outcomes. SI-BONE introduced iFuse Bedrock Granite in May 2022 to address some of these issues. The implant is typically used both to immobilize and fuse the sacroiliac (SI) joint and to serve as foundational support at the base of a spine fusion construct. The initial clearance included an indication for use with a single manufacturer’s pedicle screw system. The expanded indications include use with a wide range of rods that are commonly used in multilevel spine fusion surgeries. The expanded indications will allow surgeons to use their preferred techniques and implant systems with confidence in conjunction with iFuse Bedrock Granite as the foundation for their construct.Recent Insider Transactions • Nov 19Executive Chairman recently sold €101k worth of stockOn the 16th of November, Jeffrey Dunn sold around 8k shares on-market at roughly €12.66 per share. This transaction amounted to 6.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Jeffrey has been a net seller over the last 12 months, reducing personal holdings by €484k.Reported Earnings • Nov 09Third quarter 2022 earnings released: US$0.41 loss per share (vs US$0.48 loss in 3Q 2021)Third quarter 2022 results: US$0.41 loss per share (improved from US$0.48 loss in 3Q 2021). Revenue: US$26.4m (up 19% from 3Q 2021). Net loss: US$14.2m (loss narrowed 11% from 3Q 2021). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.お知らせ • Nov 08SI-BONE, Inc. Updates Revenue Guidance for the Year 2022SI-BONE, Inc. updated revenue guidance for the year 2022. The Company expects 2022 worldwide revenue to be in the range of $104 million to $105 million, implying growth of approximately 16% to 17%. The annual revenue guidance implies fourth quarter 2022 worldwide revenue between$29.5 million and $30.5 million, reflecting growth of approximately 17% to 21% over the prior year period.お知らせ • Oct 18SI-BONE, Inc. to Report Q3, 2022 Results on Nov 07, 2022SI-BONE, Inc. announced that they will report Q3, 2022 results After-Market on Nov 07, 2022Recent Insider Transactions • Aug 19Executive Chairman recently sold €135k worth of stockOn the 16th of August, Jeffrey Dunn sold around 8k shares on-market at roughly €16.99 per share. This was the largest sale by an insider in the last 3 months. Jeffrey has been a seller over the last 12 months, reducing personal holdings by €507k.お知らせ • Aug 10SI-BONE, Inc. Provides Earnings Guidance for the Fiscal Year 2022SI-BONE, Inc. provided earnings guidance for the fiscal year 2022. For the period, the company continues to expect total 2022 revenue of approximately $106 million to $108 million, representing growth of 18% to 20% compared to full year 2021.Reported Earnings • Aug 09Second quarter 2022 earnings released: US$0.54 loss per share (vs US$0.42 loss in 2Q 2021)Second quarter 2022 results: US$0.54 loss per share (down from US$0.42 loss in 2Q 2021). Revenue: US$25.6m (up 15% from 2Q 2021). Net loss: US$18.5m (loss widened 32% from 2Q 2021). Over the next year, revenue is forecast to grow 24%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 1% per year.お知らせ • Jul 19SI-BONE, Inc. to Report Q2, 2022 Results on Aug 08, 2022SI-BONE, Inc. announced that they will report Q2, 2022 results After-Market on Aug 08, 2022お知らせ • Jun 14SI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ® Implant SystemSI-BONE, Inc. announced an FDA clearance for iFuse-TORQ® for pelvic fracture fixation, including acute, non-acute and non-traumatic fractures. Fractures covered in this clearance include pelvic fragility fractures (fractures related to low-energy traumatic events) and pelvic insufficiency fractures. Together, these constitute an approximately $300 million market opportunity. Sacral fragility and insufficiency fractures are common and often devastating for patients and healthcare systems, where: 120,000 sacral fragility or insufficiency fractures occur annually in the US; 78% of patients are treated with bed rest leading to 14 to 45 day hospital stays; 27% 1 year mortality results from bed rest associated complications.お知らせ • Jun 01SI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock GraniteSI-BONE, Inc. announced FDA 510(k) premarket clearance of the iFuse Bedrock Granite Implant System (Granite). The Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. This clearance follows the earlier designation by the Food & Drug Administration (FDA) of Granite as a Breakthrough Device (BDD), and most recently, a proposal by the Centers for Medicare and Medicaid Services (CMS) for a New Technology Add-on Payment (NTAP). CMS has also issued new technology “Section X” ICD-10 unique procedure coding for hospitals to report NTAP eligible cases that use Granite as an Internal Fixation Device with Tulip Connector, for either open or percutaneous sacroiliac joint fusion and sacropelvic fixation.Recent Insider Transactions • May 20Executive Chairman recently sold €68k worth of stockOn the 16th of May, Jeffrey Dunn sold around 6k shares on-market at roughly €12.09 per share. This was the largest sale by an insider in the last 3 months. Jeffrey has been a seller over the last 12 months, reducing personal holdings by €543k.Reported Earnings • May 11First quarter 2022 earnings released: US$0.52 loss per share (vs US$0.37 loss in 1Q 2021)First quarter 2022 results: US$0.52 loss per share (down from US$0.37 loss in 1Q 2021). Revenue: US$22.4m (up 9.8% from 1Q 2021). Net loss: US$17.4m (loss widened 42% from 1Q 2021). Over the next year, revenue is forecast to grow 23%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.お知らせ • May 10SI-BONE, Inc. Provides Revenue Guidance for the Full Year 2022SI-BONE, Inc. provided revenue guidance for the full year 2022. For the year, the company expects total revenue of approximately $106 million to $108 million, representing growth of 18% to 20% compared to full year 2021.お知らせ • Apr 23SI-BONE, Inc., Annual General Meeting, Jun 16, 2022SI-BONE, Inc., Annual General Meeting, Jun 16, 2022, at 08:00 Pacific Daylight. Agenda: To elect the Board of Director’s three nominees for director to serve until the 2025 Annual Meeting of Stockholders or until their successors are elected and qualified; to ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022; to provide an advisory, non-binding vote on the compensation of named executive officers, as disclosed in this proxy statement; to indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of named executive officers; and to conduct any other business properly brought before the meeting.お知らせ • Apr 20SI-BONE, Inc. Announces New Technology Add-On Payment for Breakthrough Adult Spinal Deformity TreatmentSI-BONE, Inc. announced that the Centers for Medicare and Medicaid Services (CMS) has proposed a New Technology Add-on Payment (NTAP) for the iFuse Bedrock Granite™ implant. The Granite implant is intended to provide sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. The Granite implant was awarded Breakthrough Device Designation by the FDA and is anticipated to receive regulatory clearance this year. In designating the Granite implant as a Breakthrough Device, the FDA determined that it provides for more effective treatment of an irreversibly debilitating condition than the current standard of care. The NTAP program, which recognizes new technologies that provide substantial clinical improvement over already available therapies, is designed to support timely access to such innovative technologies for Medicare beneficiaries. The approval for the NTAP is subject to FDA clearance of iFuse Bedrock Granite and finalization of the proposed rule. Once finalized, CMS will reimburse hospitals an incremental amount in addition to the Medicare Severity Diagnosis Related Group (MS-DRG) payment.お知らせ • Apr 19SI-BONE, Inc. to Report Q1, 2022 Results on May 09, 2022SI-BONE, Inc. announced that they will report Q1, 2022 results After-Market on May 09, 2022Reported Earnings • Mar 02Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: US$1.71 loss per share (down from US$1.50 loss in FY 2020). Revenue: US$90.2m (up 23% from FY 2020). Net loss: US$56.6m (loss widened 30% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 19%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 4% per year.お知らせ • Mar 02SI-BONE, Inc. Provides Revenue Guidance for the Full Year 2022SI-BONE, Inc. provided revenue guidance for the full year 2022. For the year, the company expects total 2022 revenue of approximately $106 million to $108 million, representing growth of 18% to 20% compared to full year 2021.Recent Insider Transactions • Feb 18Executive Chairman recently sold €80k worth of stockOn the 16th of February, Jeffrey Dunn sold around 4k shares on-market at roughly €17.93 per share. This was the largest sale by an insider in the last 3 months. Jeffrey has been a seller over the last 12 months, reducing personal holdings by €724k.お知らせ • Feb 02SI-BONE, Inc. to Report Q4, 2021 Results on Feb 28, 2022SI-BONE, Inc. announced that they will report Q4, 2021 results After-Market on Feb 28, 2022Recent Insider Transactions • Nov 18Executive Chairman recently sold €122k worth of stockOn the 16th of November, Jeffrey Dunn sold around 6k shares on-market at roughly €18.93 per share. This was the largest sale by an insider in the last 3 months. Jeffrey has been a seller over the last 12 months, reducing personal holdings by €779k.Reported Earnings • Nov 09Third quarter 2021 earnings released: US$0.48 loss per share (vs US$0.33 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$22.3m (up 9.4% from 3Q 2020). Net loss: US$15.9m (loss widened 68% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Aug 18Executive Chairman recently sold €120k worth of stockOn the 16th of August, Jeffrey Dunn sold around 7k shares on-market at roughly €17.37 per share. This was the largest sale by an insider in the last 3 months. Jeffrey has been a seller over the last 12 months, reducing personal holdings by €743k.Reported Earnings • Aug 04Second quarter 2021 earnings released: US$0.42 loss per share (vs US$0.44 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: US$22.2m (up 58% from 2Q 2020). Net loss: US$14.0m (loss widened 12% from 2Q 2020).お知らせ • Aug 04SI-BONE, Inc. Provides Earnings Guidance for the Year 2021SI-BONE, Inc. provided earnings guidance for the year 2021. The company maintains the full year 2021 total revenue guidance to be approximately $92 million to $94 million, representing growth of 25% to 28% compared to full year 2020.Recent Insider Transactions • Jul 22Executive Chairman recently sold €52k worth of stockOn the 16th of July, Jeffrey Dunn sold around 2k shares on-market at roughly €24.65 per share. In the last 3 months, they made an even bigger sale worth €217k. Jeffrey has been a seller over the last 12 months, reducing personal holdings by €679k.お知らせ • Jul 03Si-Bone, Inc. Announces the Introduction of the Si-Bone Simulator Powered by Medability for Ifuse Surgeon Training and EducationSI-BONE, Inc. announced the worldwide launch of the SI-BONE SImulator. The SI-BONE SImulator module is an innovative training simulation system that provides surgeons a next generation platform to learn new SI-BONE sacropelvic procedures, sharpen existing surgical technique skills and prepare for iFuse procedures, all in the comfort of their office. The SI-BONE SImulator was developed and designed by SI-BONE and Medability, based on Medability’s SimBone simulation platform. It takes advantage of Medability’s revolutionary radiation-free simulation technology to provide an immersive hands-on training experience, including virtual x-ray, CT imaging and navigation. The unique, portable system can be used in a surgeon’s office or any other convenient location, without the need for a C-arm or other radiation-based imaging equipment. The SImulator uses standard iFuse instruments and implants, and allows training on patient-specific anatomies including normal male, normal female, or dysmorphic sacrum, using three interchangeable synthetic pelvic inserts. The SI-BONE SImulator, Powered by Medability, is now being used throughout the U.S. and Europe for primary lateral minimally invasive sacroiliac joint fusion procedures with the iFuse Implant System, the iFuse Bedrock Procedure and intra-articular SI joint injections. It has been successfully used with large groups, as well as in one-on-one individual sessions. The synthetic tissue and pelvic inserts, are reused or recycled.Executive Departure • Jun 15Independent Director Mark Foley has left the companyOn the 10th of June, Mark Foley's tenure as Independent Director ended after 2.0 years in the role. We don't have any record of a personal shareholding under Mark's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Jun 15Independent Director Karen Licitra has left the companyOn the 10th of June, Karen Licitra's tenure as Independent Director ended after 5.9 years in the role. We don't have any record of a personal shareholding under Karen's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.Recent Insider Transactions • May 21Executive Chairman recently sold €217k worth of stockOn the 17th of May, Jeffrey Dunn sold around 8k shares on-market at roughly €25.84 per share. This was the largest sale by an insider in the last 3 months. Jeffrey has been a seller over the last 12 months, reducing personal holdings by €648k.Reported Earnings • May 05First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.47 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$20.4m (up 22% from 1Q 2020). Net loss: US$12.2m (loss narrowed 4.1% from 1Q 2020).お知らせ • May 04Si-Bone, Inc. Provides Revenue Guidance for the Year 2021Si-Bone, Inc. provided revenue guidance for the year 2021. The Company continues to expect full year 2021 total revenue to be approximately $92 million to $94 million, representing growth of 25% to 28% compared to full year 2020.Recent Insider Transactions • Apr 21Executive Chairman & President recently sold €59k worth of stockOn the 16th of April, Jeffrey Dunn sold around 2k shares on-market at roughly €28.09 per share. In the last 3 months, they made an even bigger sale worth €90k. Jeffrey has been a seller over the last 12 months, reducing personal holdings by €503k.お知らせ • Mar 10SI-BONE, Inc. Announces Board ChangesSI-BONE, Inc. announced that on March 4, 2021, the Board of Directors of the Company appointed Mika Nishimura as a director and as a member of the Compensation Committee of the Board. Ms. Nishimura is currently an Operational Partner with Gilde Healthcare Partners. On March 4, 2021, Karen A. Licitra, a member of the Board since 2015, informed the Board that she does not intend to stand for reelection at the 2021 Annual Meeting. Ms. Licitra's decision not to stand for reelection is not the result of any disagreement with the Company. Ms. Licitra will continue to serve as a director and as a member of the Compensation Committee of the Board until her current term expires at the 2021 Annual Meeting of Stockholders.お知らせ • Feb 10SI-BONE, Inc. to Report Q4, 2020 Results on Mar 08, 2021SI-BONE, Inc. announced that they will report Q4, 2020 results After-Market on Mar 08, 2021お知らせ • Jan 09+ 1 more updateSI-BONE, Inc. Announces Resignation of Laura Francis from CFOSI-BONE, Inc. announced that its intention to appoint Laura Francis as Chief Executive Officer and to the board of directors. Laura Francis currently serves as SI-BONE’s Chief Financial Officer and Chief Operating Officer. The company will begin a search for a new CFO immediately and senior leadership changes will occur upon the earlier of the CFO replacement or May 1, 2021.株主還元2K3DE Medical EquipmentDE 市場7D2.1%1.5%1.7%1Yn/a-26.8%2.6%株主還元を見る業界別リターン: 2K3がGerman Medical Equipment業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: 2K3 German市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is 2K3's price volatile compared to industry and market?2K3 volatility2K3 Average Weekly Movement7.8%Medical Equipment Industry Average Movement5.9%Market Average Movement5.6%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.7%安定した株価: 2K3 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 2K3の 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2008376Laura Francissi-bone.com医療機器メーカーであるSI-BONE, Inc.は、米国内外の仙骨骨盤の筋骨格系障害の解決に注力している。同社は、仙腸関節の機能障害や変性、成人の変形や変性、骨盤外傷に対応する独自の低侵襲手術用インプラントシステムや、移植可能な骨製品を提供している。また、iFuseインプラントの三角形の断面と独自の3Dプリント多孔質表面と柵状デザインを組み合わせたチタンインプラントであるiFuse-3D、骨盤外傷と仙腸関節固定への応用向けに設計された3DプリントスレッドインプラントのラインであるiFuse TORQを提供している；骨盤の外傷や仙腸関節の固定に使用される3Dプリントネジインプラント「iFuse TORQ」、骨盤の外傷や仙腸関節の固定に使用される「iFuse Bedrock Granite Implant System」、骨盤の外傷や仙腸関節の機能障害に使用される「iFuse TORQ TNT」、ヒトの細胞や組織、細胞や組織ベースの製品として販売される「iFuse INTRA」などがある。同社は主に直販部隊と第三者販売代理店および再販業者を通じて製品を販売している。SI-BONE社は2008年に設立され、カリフォルニア州サンタクララに本社を置いている。もっと見るSI-BONE, Inc. 基礎のまとめSI-BONE の収益と売上を時価総額と比較するとどうか。2K3 基礎統計学時価総額€651.86m収益（TTM）-€14.61m売上高(TTM)€180.42m3.7xP/Sレシオ-45.4xPER（株価収益率2K3 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計2K3 損益計算書（TTM）収益US$206.22m売上原価US$42.10m売上総利益US$164.13mその他の費用US$180.82m収益-US$16.70m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.38グロス・マージン79.59%純利益率-8.10%有利子負債／自己資本比率19.9%2K3 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/02 17:28終値2026/07/02 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SI-BONE, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関Travis SteedBofA Global ResearchCaitlin CroninCanaccord GenuityCiti ResearchCitigroup Inc11 その他のアナリストを表示
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. CEO & Director Laura Francis was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • May 12SI-BONE, Inc. Raises Earnings Guidance for the Year 2026SI-BONE, Inc. raised earnings guidance for the year 2026. For the year, the company worldwide revenue expectation to be in the range of $230 million to $233 million, implying year-over-year growth of 14% to 16% compared to previous guidance of $228.5 million - $232.5 million.
お知らせ • Apr 22SI-BONE, Inc., Annual General Meeting, Jun 04, 2026SI-BONE, Inc., Annual General Meeting, Jun 04, 2026.
お知らせ • Apr 21SI-BONE, Inc. to Report Q1, 2026 Results on May 11, 2026SI-BONE, Inc. announced that they will report Q1, 2026 results After-Market on May 11, 2026
お知らせ • Feb 24+ 1 more updateSI-BONE, Inc. Provides Earnings Guidance for the Year 2026SI-BONE, Inc. provided earnings guidance for the year 2026. For the year, the company expects worldwide revenue to be in the range of $228.5 millionto $232.5 million, implying year-over-year growth of ~14% to ~16%.
お知らせ • Feb 03SI-BONE, Inc. to Report Q4, 2025 Results on Feb 23, 2026SI-BONE, Inc. announced that they will report Q4, 2025 results After-Market on Feb 23, 2026
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. CEO & Director Laura Francis was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • May 12SI-BONE, Inc. Raises Earnings Guidance for the Year 2026SI-BONE, Inc. raised earnings guidance for the year 2026. For the year, the company worldwide revenue expectation to be in the range of $230 million to $233 million, implying year-over-year growth of 14% to 16% compared to previous guidance of $228.5 million - $232.5 million.
お知らせ • Apr 22SI-BONE, Inc., Annual General Meeting, Jun 04, 2026SI-BONE, Inc., Annual General Meeting, Jun 04, 2026.
お知らせ • Apr 21SI-BONE, Inc. to Report Q1, 2026 Results on May 11, 2026SI-BONE, Inc. announced that they will report Q1, 2026 results After-Market on May 11, 2026
お知らせ • Feb 24+ 1 more updateSI-BONE, Inc. Provides Earnings Guidance for the Year 2026SI-BONE, Inc. provided earnings guidance for the year 2026. For the year, the company expects worldwide revenue to be in the range of $228.5 millionto $232.5 million, implying year-over-year growth of ~14% to ~16%.
お知らせ • Feb 03SI-BONE, Inc. to Report Q4, 2025 Results on Feb 23, 2026SI-BONE, Inc. announced that they will report Q4, 2025 results After-Market on Feb 23, 2026
お知らせ • Nov 11Si-Bone, Inc. Updates Earnings Guidance for the Year 2025Si-Bone, Inc. updated earnings guidance for the year 2025. For the year, the company now expects Revenue of $198 Million - $200 Million against previous guidance of $195 Million - $198 Million.
お知らせ • Oct 21SI-BONE, Inc. to Report Q3, 2025 Results on Nov 10, 2025SI-BONE, Inc. announced that they will report Q3, 2025 results After-Market on Nov 10, 2025
お知らせ • Aug 05+ 1 more updateSI-BONE, Inc. Revises Financial Guidance for the Full Year of 2025SI-BONE, Inc. revises financial guidance for the full year of 2025. For the period, the company expects worldwide revenue to be in the range of $195 million to $198 million, implying year-over-year growth of approximately 17% to approximately 18% against pervious guidance of $193.5 million to $197.5 million, implying year-over-year growth of approximately 16% to approximately 18%.
お知らせ • Jul 15SI-BONE, Inc. to Report Q2, 2025 Results on Aug 04, 2025SI-BONE, Inc. announced that they will report Q2, 2025 results After-Market on Aug 04, 2025
お知らせ • Jun 30+ 4 more updatesSI-BONE, Inc.(NasdaqGM:SIBN) dropped from Russell Microcap Value IndexSI-BONE, Inc.(NasdaqGM:SIBN) dropped from Russell Microcap Value Index
お知らせ • May 06SI-BONE, Inc. Revises Earnings Guidance for the Year 2025SI-BONE, Inc. revised earnings guidance for the year 2025. The company expects 2025 worldwide revenue to be in the range of $193.5 million to $197.5 million, compared to the prior guidance of $193.5 million to $195.5 million.
お知らせ • Apr 28SI-BONE, Inc., Annual General Meeting, Jun 05, 2025SI-BONE, Inc., Annual General Meeting, Jun 05, 2025.
お知らせ • Apr 15SI-BONE, Inc. to Report Q1, 2025 Results on May 05, 2025SI-BONE, Inc. announced that they will report Q1, 2025 results After-Market on May 05, 2025
お知らせ • Feb 25SI-BONE, Inc. Provides Earnings Guidance for the Year 2025SI-BONE, Inc. provided earnings guidance for the year 2025. For the year 2025, the company expects worldwide revenue to be in the range of $193.5 million to $195.5 million, implying year-over-year growth of ~16% to ~17%.
お知らせ • Feb 04SI-BONE, Inc. to Report Q4, 2024 Results on Feb 24, 2025SI-BONE, Inc. announced that they will report Q4, 2024 results After-Market on Feb 24, 2025
Reported Earnings • Nov 14Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.25 loss in 3Q 2023)Third quarter 2024 results: US$0.16 loss per share (improved from US$0.25 loss in 3Q 2023). Revenue: US$40.3m (up 19% from 3Q 2023). Net loss: US$6.58m (loss narrowed 34% from 3Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
お知らせ • Nov 14SI-BONE, Inc. Updates Financial Guidance for the Year 2024SI-BONE, Inc. updated financial guidance for the year 2024. For the period, the company expects worldwide revenue guidance to be in the range of $165 million to $166 million compared to the prior guidance of $165 million to $167 million. The updated guidance implies annual revenue growth of approximately 19% to approximately 20%.
お知らせ • Oct 23SI-BONE, Inc. to Report Q3, 2024 Results on Nov 12, 2024SI-BONE, Inc. announced that they will report Q3, 2024 results After-Market on Nov 12, 2024
お知らせ • Oct 10SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture FixationSI-BONE, Inc. announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNT™? Implant System (TNT). Designed to address the anatomic and biomechanical challenges of pelvic fragility fractures, particularly in patients with poor bone quality, TNT offers a significant advancement over traditional cannulated screws. TNT, which received 510(k) clearance in August 2024 and was awarded Breakthrough Device Designation by the FDA, is the first 3D-printed transiliac-transsacral screw cleared for market use in the U.S. It features a pelvic fragility-specific design to improve initial fixation and reduce the risk of screw backout. Among the first surgeons to perform procedures with TNT were Edward Westrick, MD, at Allegheny General Hospital in Pittsburgh, PA, Reza Firoozabadi, MD, at Harborview Medical Center in Seattle, WA, J.D. Black, MD, at Kadlec Regional Medical Center in Richland, WA, and Brian Cunningham, MD, at Methodist Hospital - HealthPartners in St. Louis Park, MN.
Recent Insider Transactions • Aug 22CEO & Director recently sold €126k worth of stockOn the 16th of August, Laura Francis sold around 10k shares on-market at roughly €12.59 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Laura has been a net seller over the last 12 months, reducing personal holdings by €876k.
Reported Earnings • Aug 06Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.30 loss in 2Q 2023)Second quarter 2024 results: US$0.22 loss per share (improved from US$0.30 loss in 2Q 2023). Revenue: US$40.0m (up 20% from 2Q 2023). Net loss: US$8.94m (loss narrowed 20% from 2Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
お知らせ • Aug 06SI-BONE, Inc. Revises Financial Guidance for 2024SI-BONE, Inc. revised financial guidance for 2024. The company expects revenue to be in the range of $165 million to $167 million, an increase from the previous guidance of $164 million to $166 million. Compared to 2023, the updated guidance translates to growth of ~19% to ~20%, versus growth of ~18% to ~20% implied in the earlier guidance.
New Risk • Jul 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$30m net loss in 2 years). Share price has been volatile over the past 3 months (6.7% average weekly change). Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Significant insider selling over the past 3 months (€199k sold).
お知らせ • Jul 16SI-BONE, Inc. to Report Q2, 2024 Results on Aug 05, 2024SI-BONE, Inc. announced that they will report Q2, 2024 results After-Market on Aug 05, 2024
New Risk • Jun 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$30m net loss in 2 years). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Significant insider selling over the past 3 months (€235k sold).
お知らせ • May 08Si-Bone, Inc. Increases Revenue Guidance for 2024SI-BONE, Inc. increased revenue guidance for 2024. Company updated 2024 worldwide revenue guidance to be in the range of $164 million to $166 million, an increase from the previous guidance of $162 million to $165 million. Compared to 2023, the updated guidance translates to growth of ~18% to ~20%, versus growth of ~17% to ~19% implied in the earlier guidance.
Reported Earnings • May 07First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.32 loss in 1Q 2023)First quarter 2024 results: US$0.27 loss per share (improved from US$0.32 loss in 1Q 2023). Revenue: US$37.9m (up 16% from 1Q 2023). Net loss: US$10.9m (loss narrowed 2.0% from 1Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. CEO & Director Laura Francis was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • May 01SI-BONE, Inc., Annual General Meeting, Jun 25, 2024SI-BONE, Inc., Annual General Meeting, Jun 25, 2024, at 08:00 Pacific Standard Time. Agenda: To elect the Board of Director’s two nominees for director to serve until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified; To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to discuss other matters.
お知らせ • Apr 16SI-BONE, Inc. to Report Q1, 2024 Results on May 06, 2024SI-BONE, Inc. announced that they will report Q1, 2024 results After-Market on May 06, 2024
New Risk • Mar 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$43m Forecast net loss in 3 years: US$20m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$20m net loss in 3 years). Shareholders have been diluted in the past year (19% increase in shares outstanding). Significant insider selling over the past 3 months (€1.2m sold).
お知らせ • Feb 29SI-BONE, Inc. Provides Earnings Guidance for the Year 2024SI-BONE, Inc. provided earnings guidance for the year 2024. For the year, the company expects worldwide revenue to be between $162 million to $165 million, implying year-over-year growth of approx. 17% to approx. 19%.
Reported Earnings • Feb 27Full year 2023 earnings released: US$1.13 loss per share (vs US$1.79 loss in FY 2022)Full year 2023 results: US$1.13 loss per share (improved from US$1.79 loss in FY 2022). Revenue: US$138.9m (up 31% from FY 2022). Net loss: US$43.3m (loss narrowed 29% from FY 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Feb 27Forecast to breakeven in 2026The 8 analysts covering SI-BONE expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 17% per year to 2025. The company is expected to make a profit of US$3.50m in 2026. Average annual earnings growth of 40% is required to achieve expected profit on schedule.
Recent Insider Transactions • Feb 23CEO & Director recently sold €751k worth of stockOn the 16th of February, Laura Francis sold around 39k shares on-market at roughly €19.45 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Laura has been a net seller over the last 12 months, reducing personal holdings by €1.1m.
お知らせ • Feb 06SI-BONE, Inc. to Report Q4, 2023 Results on Feb 26, 2024SI-BONE, Inc. announced that they will report Q4, 2023 results After-Market on Feb 26, 2024
お知らせ • Jan 30SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and ApplicationSI-BONE, Inc. announces FDA 510(k) premarket clearance of the iFuse Bedrock Granite® Implant System (Granite) in a smaller (9.5 mm) diameter with both an expanded indication in pediatric patients and an expanded application that includes use in the S1 trajectory. When placed across the SI joint, the Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for multi-segment spinal fusion. This 510(k) clearance follows the initial clearance of the iFuse Bedrock Granite System in May 2022 that included implants of 10.5 mm and 11.5 mm in diameter. The iFuse Bedrock Granite System was also awarded a Breakthrough Device Designation (BDD) by the Food & Drug Administration (FDA) and a New Technology Add-on Payment (NTAP) by the Centers for Medicare and Medicaid Services (CMS).
Breakeven Date Change • Jan 20Forecast to breakeven in 2026The 8 analysts covering SI-BONE expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$8.50m in 2026. Average annual earnings growth of 27% is required to achieve expected profit on schedule.
お知らせ • Jan 09SI-Bone, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023SI-BONE, Inc. provided revenue guidance for the fourth quarter and full year 2023. For the fourth quarter, the company worldwide revenue expected to be in the range of $38.5-$38.7 million, representing growth of approximately 21% compared to the prior year period and U.S. revenue expected to be in the range of $36.5-$36.6 million, representing growth of approximately 22% compared to the prior year period.For the fiscal year, the company worldwide revenue expected to be in the range of $138.5-138.7 million, representing growth of approximately 30% compared to the prior year period and U.S. revenue expected to be in the range of $130.5-$130.6 million, representing growth of approximately 32% compared to the prior year period.
Recent Insider Transactions • Nov 24Executive Chairman recently sold €130k worth of stockOn the 16th of November, Jeffrey Dunn sold around 8k shares on-market at roughly €16.29 per share. This transaction amounted to 7.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Jeffrey has been a net seller over the last 12 months, reducing personal holdings by €592k.
お知らせ • Nov 09SI-BONE, Inc. Increases Earnings Guidance for the Full Year 2023SI-BONE, Inc. increased earnings guidance for the full year 2023. For the period, the company increased worldwide revenue to be in the range of $136 million to $137 million from the previous guidance of $132 million to $134 million. The updated guidance translates to growth of approximately 28% to 29% compared to fiscal year 2022, versus the previous revenue growth of approximately 24% to 26%.
Reported Earnings • Nov 09Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.41 loss in 3Q 2022)Third quarter 2023 results: US$0.25 loss per share (improved from US$0.41 loss in 3Q 2022). Revenue: US$34.0m (up 29% from 3Q 2022). Net loss: US$10.0m (loss narrowed 29% from 3Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 3% per year.
New Risk • Nov 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.1% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$12m net loss in 3 years). Shareholders have been diluted in the past year (17% increase in shares outstanding). Significant insider selling over the past 3 months (€1.1m sold).
お知らせ • Oct 17SI-BONE, Inc. to Report Q3, 2023 Results on Nov 06, 2023SI-BONE, Inc. announced that they will report Q3, 2023 results After-Market on Nov 06, 2023
お知らせ • Sep 06SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera 5.5/6.0 System RodsSI-BONE, Inc. confirmed that certain CD Horizon® Solera® 5.5mm and 6.0mm posterior spinal fixation rods manufactured by Medtronic Sofamor Danek USA Inc., a division of Medtronic plc, meet SI-BONE’s criteria for compatibility with iFuse Bedrock Granite® indicated in the Granite implant’s instructions for use. A complete list of Medtronic Solera® rods meeting the criteria for compatibility described in Granite’s cleared labeling is available on SI-BONE’s website. The iFuse Bedrock Granite implant was cleared by FDA on May 26, 2022. FDA recognized the Granite implant’s significant advantages over existing approved or cleared alternatives in designating the product as a Breakthrough Device. CMS subsequently adopted a New Technology Add-on Payment of up to $9,828 per procedure, based on the individual hospital’s costs, for procedures reimbursed under the Medicare program and incorporating this new technology.
Recent Insider Transactions • Aug 21CEO & Director recently sold €173k worth of stockOn the 16th of August, Laura Francis sold around 9k shares on-market at roughly €19.21 per share. This transaction amounted to 4.6% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €561k. Laura has been a net seller over the last 12 months, reducing personal holdings by €591k.
Recent Insider Transactions • Aug 13Independent Director recently sold €561k worth of stockOn the 9th of August, John Freund sold around 30k shares on-market at roughly €18.71 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.4m more than they bought in the last 12 months.
お知らせ • Aug 10SI-BONE, Inc. Revises Revenue Guidance for the Year 2023SI-BONE, Inc. revised revenue guidance for the year 2023. The company is increasing its 2023 worldwide revenue guidance to be in the range of $132 million to $134 million from the previous guidance of $128 million to $131 million.
Reported Earnings • Aug 08Second quarter 2023 earnings released: US$0.30 loss per share (vs US$0.54 loss in 2Q 2022)Second quarter 2023 results: US$0.30 loss per share (improved from US$0.54 loss in 2Q 2022). Revenue: US$33.3m (up 30% from 2Q 2022). Net loss: US$11.2m (loss narrowed 40% from 2Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
お知らせ • Jul 18SI-BONE, Inc. to Report Q2, 2023 Results on Aug 07, 2023SI-BONE, Inc. announced that they will report Q2, 2023 results After-Market on Aug 07, 2023
Recent Insider Transactions • May 22CEO & Director recently sold €206k worth of stockOn the 16th of May, Laura Francis sold around 9k shares on-market at roughly €22.87 per share. This transaction amounted to 4.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Laura has been a net seller over the last 12 months, reducing personal holdings by €507k.
お知らせ • May 06SI-BONE, Inc. has completed a Follow-on Equity Offering in the amount of $83.05 million.SI-BONE, Inc. has completed a Follow-on Equity Offering in the amount of $83.05 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,775,000 Price\Range: $22
Reported Earnings • May 03First quarter 2023 earnings released: US$0.32 loss per share (vs US$0.52 loss in 1Q 2022)First quarter 2023 results: US$0.32 loss per share (improved from US$0.52 loss in 1Q 2022). Revenue: US$32.7m (up 46% from 1Q 2022). Net loss: US$11.1m (loss narrowed 36% from 1Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
お知らせ • Feb 07SI-BONE, Inc. to Report Q4, 2022 Results on Feb 27, 2023SI-BONE, Inc. announced that they will report Q4, 2022 results After-Market on Feb 27, 2023
お知らせ • Jan 10SI-BONE, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022SI-BONE, Inc. provided preliminary unaudited revenue guidance for the fourth quarter and full year of 2022. For the quarter, the company expects worldwide revenue to be in the range of $31.7 million to $31.9 million, representing growth of approximately 26% compared to the prior year period. U.S. revenue to be in the range of $29.8 million to $29.9 million, representing growth of approximately 28% compared to the prior year period.For the full year, the company expects worldwide revenue to be in the range of $106.1 million to $106.3 million, representing growth of approximately 18% compared to the prior year period. U.S. revenue to be in the range of $98.6 million to $98.7 million, representing growth of approximately 19% compared to the prior year period.
お知らせ • Dec 28SI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite(R) Implant SystemSI-BONE, Inc. announced an additional FDA clearance for iFuse Bedrock Granite. New cleared indications include use with a wide variety of commercially available pedicle screw system rods. Adult spinal deformity is a complex clinical problem to treat, with lumbopelvic fixation failure rates reported at 24%.1 Surgeons have adopted different strategies involving preoperative planning to improve spinal alignment, biologics, and next-generation pelvic fixation implants to help improve surgical outcomes. SI-BONE introduced iFuse Bedrock Granite in May 2022 to address some of these issues. The implant is typically used both to immobilize and fuse the sacroiliac (SI) joint and to serve as foundational support at the base of a spine fusion construct. The initial clearance included an indication for use with a single manufacturer’s pedicle screw system. The expanded indications include use with a wide range of rods that are commonly used in multilevel spine fusion surgeries. The expanded indications will allow surgeons to use their preferred techniques and implant systems with confidence in conjunction with iFuse Bedrock Granite as the foundation for their construct.
Recent Insider Transactions • Nov 19Executive Chairman recently sold €101k worth of stockOn the 16th of November, Jeffrey Dunn sold around 8k shares on-market at roughly €12.66 per share. This transaction amounted to 6.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Jeffrey has been a net seller over the last 12 months, reducing personal holdings by €484k.
Reported Earnings • Nov 09Third quarter 2022 earnings released: US$0.41 loss per share (vs US$0.48 loss in 3Q 2021)Third quarter 2022 results: US$0.41 loss per share (improved from US$0.48 loss in 3Q 2021). Revenue: US$26.4m (up 19% from 3Q 2021). Net loss: US$14.2m (loss narrowed 11% from 3Q 2021). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
お知らせ • Nov 08SI-BONE, Inc. Updates Revenue Guidance for the Year 2022SI-BONE, Inc. updated revenue guidance for the year 2022. The Company expects 2022 worldwide revenue to be in the range of $104 million to $105 million, implying growth of approximately 16% to 17%. The annual revenue guidance implies fourth quarter 2022 worldwide revenue between$29.5 million and $30.5 million, reflecting growth of approximately 17% to 21% over the prior year period.
お知らせ • Oct 18SI-BONE, Inc. to Report Q3, 2022 Results on Nov 07, 2022SI-BONE, Inc. announced that they will report Q3, 2022 results After-Market on Nov 07, 2022
Recent Insider Transactions • Aug 19Executive Chairman recently sold €135k worth of stockOn the 16th of August, Jeffrey Dunn sold around 8k shares on-market at roughly €16.99 per share. This was the largest sale by an insider in the last 3 months. Jeffrey has been a seller over the last 12 months, reducing personal holdings by €507k.
お知らせ • Aug 10SI-BONE, Inc. Provides Earnings Guidance for the Fiscal Year 2022SI-BONE, Inc. provided earnings guidance for the fiscal year 2022. For the period, the company continues to expect total 2022 revenue of approximately $106 million to $108 million, representing growth of 18% to 20% compared to full year 2021.
Reported Earnings • Aug 09Second quarter 2022 earnings released: US$0.54 loss per share (vs US$0.42 loss in 2Q 2021)Second quarter 2022 results: US$0.54 loss per share (down from US$0.42 loss in 2Q 2021). Revenue: US$25.6m (up 15% from 2Q 2021). Net loss: US$18.5m (loss widened 32% from 2Q 2021). Over the next year, revenue is forecast to grow 24%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 1% per year.
お知らせ • Jul 19SI-BONE, Inc. to Report Q2, 2022 Results on Aug 08, 2022SI-BONE, Inc. announced that they will report Q2, 2022 results After-Market on Aug 08, 2022
お知らせ • Jun 14SI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ® Implant SystemSI-BONE, Inc. announced an FDA clearance for iFuse-TORQ® for pelvic fracture fixation, including acute, non-acute and non-traumatic fractures. Fractures covered in this clearance include pelvic fragility fractures (fractures related to low-energy traumatic events) and pelvic insufficiency fractures. Together, these constitute an approximately $300 million market opportunity. Sacral fragility and insufficiency fractures are common and often devastating for patients and healthcare systems, where: 120,000 sacral fragility or insufficiency fractures occur annually in the US; 78% of patients are treated with bed rest leading to 14 to 45 day hospital stays; 27% 1 year mortality results from bed rest associated complications.
お知らせ • Jun 01SI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock GraniteSI-BONE, Inc. announced FDA 510(k) premarket clearance of the iFuse Bedrock Granite Implant System (Granite). The Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. This clearance follows the earlier designation by the Food & Drug Administration (FDA) of Granite as a Breakthrough Device (BDD), and most recently, a proposal by the Centers for Medicare and Medicaid Services (CMS) for a New Technology Add-on Payment (NTAP). CMS has also issued new technology “Section X” ICD-10 unique procedure coding for hospitals to report NTAP eligible cases that use Granite as an Internal Fixation Device with Tulip Connector, for either open or percutaneous sacroiliac joint fusion and sacropelvic fixation.
Recent Insider Transactions • May 20Executive Chairman recently sold €68k worth of stockOn the 16th of May, Jeffrey Dunn sold around 6k shares on-market at roughly €12.09 per share. This was the largest sale by an insider in the last 3 months. Jeffrey has been a seller over the last 12 months, reducing personal holdings by €543k.
Reported Earnings • May 11First quarter 2022 earnings released: US$0.52 loss per share (vs US$0.37 loss in 1Q 2021)First quarter 2022 results: US$0.52 loss per share (down from US$0.37 loss in 1Q 2021). Revenue: US$22.4m (up 9.8% from 1Q 2021). Net loss: US$17.4m (loss widened 42% from 1Q 2021). Over the next year, revenue is forecast to grow 23%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.
お知らせ • May 10SI-BONE, Inc. Provides Revenue Guidance for the Full Year 2022SI-BONE, Inc. provided revenue guidance for the full year 2022. For the year, the company expects total revenue of approximately $106 million to $108 million, representing growth of 18% to 20% compared to full year 2021.
お知らせ • Apr 23SI-BONE, Inc., Annual General Meeting, Jun 16, 2022SI-BONE, Inc., Annual General Meeting, Jun 16, 2022, at 08:00 Pacific Daylight. Agenda: To elect the Board of Director’s three nominees for director to serve until the 2025 Annual Meeting of Stockholders or until their successors are elected and qualified; to ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022; to provide an advisory, non-binding vote on the compensation of named executive officers, as disclosed in this proxy statement; to indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of named executive officers; and to conduct any other business properly brought before the meeting.
お知らせ • Apr 20SI-BONE, Inc. Announces New Technology Add-On Payment for Breakthrough Adult Spinal Deformity TreatmentSI-BONE, Inc. announced that the Centers for Medicare and Medicaid Services (CMS) has proposed a New Technology Add-on Payment (NTAP) for the iFuse Bedrock Granite™ implant. The Granite implant is intended to provide sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. The Granite implant was awarded Breakthrough Device Designation by the FDA and is anticipated to receive regulatory clearance this year. In designating the Granite implant as a Breakthrough Device, the FDA determined that it provides for more effective treatment of an irreversibly debilitating condition than the current standard of care. The NTAP program, which recognizes new technologies that provide substantial clinical improvement over already available therapies, is designed to support timely access to such innovative technologies for Medicare beneficiaries. The approval for the NTAP is subject to FDA clearance of iFuse Bedrock Granite and finalization of the proposed rule. Once finalized, CMS will reimburse hospitals an incremental amount in addition to the Medicare Severity Diagnosis Related Group (MS-DRG) payment.
お知らせ • Apr 19SI-BONE, Inc. to Report Q1, 2022 Results on May 09, 2022SI-BONE, Inc. announced that they will report Q1, 2022 results After-Market on May 09, 2022
Reported Earnings • Mar 02Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: US$1.71 loss per share (down from US$1.50 loss in FY 2020). Revenue: US$90.2m (up 23% from FY 2020). Net loss: US$56.6m (loss widened 30% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 19%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 4% per year.
お知らせ • Mar 02SI-BONE, Inc. Provides Revenue Guidance for the Full Year 2022SI-BONE, Inc. provided revenue guidance for the full year 2022. For the year, the company expects total 2022 revenue of approximately $106 million to $108 million, representing growth of 18% to 20% compared to full year 2021.
Recent Insider Transactions • Feb 18Executive Chairman recently sold €80k worth of stockOn the 16th of February, Jeffrey Dunn sold around 4k shares on-market at roughly €17.93 per share. This was the largest sale by an insider in the last 3 months. Jeffrey has been a seller over the last 12 months, reducing personal holdings by €724k.
お知らせ • Feb 02SI-BONE, Inc. to Report Q4, 2021 Results on Feb 28, 2022SI-BONE, Inc. announced that they will report Q4, 2021 results After-Market on Feb 28, 2022
Recent Insider Transactions • Nov 18Executive Chairman recently sold €122k worth of stockOn the 16th of November, Jeffrey Dunn sold around 6k shares on-market at roughly €18.93 per share. This was the largest sale by an insider in the last 3 months. Jeffrey has been a seller over the last 12 months, reducing personal holdings by €779k.
Reported Earnings • Nov 09Third quarter 2021 earnings released: US$0.48 loss per share (vs US$0.33 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$22.3m (up 9.4% from 3Q 2020). Net loss: US$15.9m (loss widened 68% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Aug 18Executive Chairman recently sold €120k worth of stockOn the 16th of August, Jeffrey Dunn sold around 7k shares on-market at roughly €17.37 per share. This was the largest sale by an insider in the last 3 months. Jeffrey has been a seller over the last 12 months, reducing personal holdings by €743k.
Reported Earnings • Aug 04Second quarter 2021 earnings released: US$0.42 loss per share (vs US$0.44 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: US$22.2m (up 58% from 2Q 2020). Net loss: US$14.0m (loss widened 12% from 2Q 2020).
お知らせ • Aug 04SI-BONE, Inc. Provides Earnings Guidance for the Year 2021SI-BONE, Inc. provided earnings guidance for the year 2021. The company maintains the full year 2021 total revenue guidance to be approximately $92 million to $94 million, representing growth of 25% to 28% compared to full year 2020.
Recent Insider Transactions • Jul 22Executive Chairman recently sold €52k worth of stockOn the 16th of July, Jeffrey Dunn sold around 2k shares on-market at roughly €24.65 per share. In the last 3 months, they made an even bigger sale worth €217k. Jeffrey has been a seller over the last 12 months, reducing personal holdings by €679k.
お知らせ • Jul 03Si-Bone, Inc. Announces the Introduction of the Si-Bone Simulator Powered by Medability for Ifuse Surgeon Training and EducationSI-BONE, Inc. announced the worldwide launch of the SI-BONE SImulator. The SI-BONE SImulator module is an innovative training simulation system that provides surgeons a next generation platform to learn new SI-BONE sacropelvic procedures, sharpen existing surgical technique skills and prepare for iFuse procedures, all in the comfort of their office. The SI-BONE SImulator was developed and designed by SI-BONE and Medability, based on Medability’s SimBone simulation platform. It takes advantage of Medability’s revolutionary radiation-free simulation technology to provide an immersive hands-on training experience, including virtual x-ray, CT imaging and navigation. The unique, portable system can be used in a surgeon’s office or any other convenient location, without the need for a C-arm or other radiation-based imaging equipment. The SImulator uses standard iFuse instruments and implants, and allows training on patient-specific anatomies including normal male, normal female, or dysmorphic sacrum, using three interchangeable synthetic pelvic inserts. The SI-BONE SImulator, Powered by Medability, is now being used throughout the U.S. and Europe for primary lateral minimally invasive sacroiliac joint fusion procedures with the iFuse Implant System, the iFuse Bedrock Procedure and intra-articular SI joint injections. It has been successfully used with large groups, as well as in one-on-one individual sessions. The synthetic tissue and pelvic inserts, are reused or recycled.
Executive Departure • Jun 15Independent Director Mark Foley has left the companyOn the 10th of June, Mark Foley's tenure as Independent Director ended after 2.0 years in the role. We don't have any record of a personal shareholding under Mark's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Jun 15Independent Director Karen Licitra has left the companyOn the 10th of June, Karen Licitra's tenure as Independent Director ended after 5.9 years in the role. We don't have any record of a personal shareholding under Karen's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.
Recent Insider Transactions • May 21Executive Chairman recently sold €217k worth of stockOn the 17th of May, Jeffrey Dunn sold around 8k shares on-market at roughly €25.84 per share. This was the largest sale by an insider in the last 3 months. Jeffrey has been a seller over the last 12 months, reducing personal holdings by €648k.
Reported Earnings • May 05First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.47 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$20.4m (up 22% from 1Q 2020). Net loss: US$12.2m (loss narrowed 4.1% from 1Q 2020).
お知らせ • May 04Si-Bone, Inc. Provides Revenue Guidance for the Year 2021Si-Bone, Inc. provided revenue guidance for the year 2021. The Company continues to expect full year 2021 total revenue to be approximately $92 million to $94 million, representing growth of 25% to 28% compared to full year 2020.
Recent Insider Transactions • Apr 21Executive Chairman & President recently sold €59k worth of stockOn the 16th of April, Jeffrey Dunn sold around 2k shares on-market at roughly €28.09 per share. In the last 3 months, they made an even bigger sale worth €90k. Jeffrey has been a seller over the last 12 months, reducing personal holdings by €503k.
お知らせ • Mar 10SI-BONE, Inc. Announces Board ChangesSI-BONE, Inc. announced that on March 4, 2021, the Board of Directors of the Company appointed Mika Nishimura as a director and as a member of the Compensation Committee of the Board. Ms. Nishimura is currently an Operational Partner with Gilde Healthcare Partners. On March 4, 2021, Karen A. Licitra, a member of the Board since 2015, informed the Board that she does not intend to stand for reelection at the 2021 Annual Meeting. Ms. Licitra's decision not to stand for reelection is not the result of any disagreement with the Company. Ms. Licitra will continue to serve as a director and as a member of the Compensation Committee of the Board until her current term expires at the 2021 Annual Meeting of Stockholders.
お知らせ • Feb 10SI-BONE, Inc. to Report Q4, 2020 Results on Mar 08, 2021SI-BONE, Inc. announced that they will report Q4, 2020 results After-Market on Mar 08, 2021
お知らせ • Jan 09+ 1 more updateSI-BONE, Inc. Announces Resignation of Laura Francis from CFOSI-BONE, Inc. announced that its intention to appoint Laura Francis as Chief Executive Officer and to the board of directors. Laura Francis currently serves as SI-BONE’s Chief Financial Officer and Chief Operating Officer. The company will begin a search for a new CFO immediately and senior leadership changes will occur upon the earlier of the CFO replacement or May 1, 2021.
